A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

PURPOSE: In preclinical studies the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Gojo, Ivana, Beumer, Jan H., Pratz, Keith W., McDevitt, Michael A., Baer, Maria R., Blackford, Amanda L., Smith, B. Douglas, Gore, Steven D., Carraway, Hetty E., Showel, Margaret M., Levis, Mark J., Dezern, Amy E., Gladstone, Douglas E., Ji, Jiuping, Wang, Lihua, Kinders, Robert J., Pouquet, Marie, Ali-Walbi, Ismail, Rudek, Michelle A., Poh, Weijie, Herman, James, Karnitz, Larry M., Kaufmann, Scott H., Chen, Alice, Karp, Judith E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290001/
https://ncbi.nlm.nih.gov/pubmed/27503200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0984
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg